- Delivery Method:
- UPS Next Day Air
- Life Extension Foundation Buyers Club, Inc.
3600 W Commercial Blvd
Fort Lauderdale, FL 33309
- Issuing Office:
- Florida District Office
| || |
Florida District Office
555 Winderley Place, Suite 200
Maitland, Florida 32751
VIA UPS NEXT DAY AIR
RETURN RECEIPT REQUESTED
Warning Letter 17-07
February 01, 2017
Paul Gilner, President
Life Extension Foundation
Buyers Club, Inc.
3600 W Commercial Blvd
Fort Lauderdale, FL 33309
Dear Mr. Gilner:
This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.lifeextension.com
in December 2016 and has determined that you take orders there for the Life Extension products. The claims on your website establish that the products are drugs under Section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 United State Code (USC) 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov
Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:
On the webpage titled, “HEALTH PROTOCOLS”, under the disease, “Breast Cancer” you include a link to a page with information about breast cancer and include, “Life Extensions Suggestions” which lists products and directions for use as part of the protocol. For example, as treatments for Breast Cancer, you suggest the following Life Extension products which are for sale on your website:
Cruciferous vegetable extract
CLA or CLA with guarana
Lightly caffeinated green tea extract
Water-soluble vitamin A
Gamma linolenic acid
Whey protein concentrate-isolate
Your website also includes similar protocols where you suggest Life Extension products as treatments for various serious diseases, including the following:
Amyotrophic Lateral Sclerosis
Atherosclerosis and cardiovascular disease
Attention Deficit Hyperactivity Disorder
Benign Prostatic Hyperplasia
Blood Clot Prevention
Blood Disorders - Anemia, Leukopenia, Thrombocytopenia
Brain Tumor - Cancer
Cachexia and Sarcopenia
Chronic Fatigue Syndrome
Chronic Kidney Disease
Chronic Obstructive Pulmonary Disease
Diverticulosis and Diverticular Disease
Epilepsy - Seizures
Gastroesophageal Reflux Disease - GERD
Gout and Hyperuricemia
Hearing Loss and Tinnitus
Herpes and Shingles
High Blood Pressure
Inflammatory Bowel Disease
Irritable Bowel Syndrome (IBS)
Liver Degenerative Disease
Multiple Sclerosis (MS)
Non-Alcoholic Fatty Liver Disease
Polycystic Ovary Syndrome (PCOS)
Urinary Tract Infection (UTI)
Uterine (Endometrial) Cancer
- In a July 15, 2016 post titled, “Can blindness be avoided? Check out this exciting study!” which highlights the use of Life Extension products to reduce the risk of macular degeneration and links to an article titled, “Study Proves Natural Ways to Avoid Blindness” in Life Extension Magazine, accessible at www.lifeextension.com/Magazine/2016/7/Huge-Study-Validates-Natural-Appr… and includes links to product pages, MacuGuard® Ocular Support and MacuGuard® Ocular Support with Astaxanthin, and the health protocol, “Macular Degeneration” listed above, where your products can be purchased directly.
- In a July 17, 2016 post titled, “Supplementing with CoQ10? Your heart will seriously thank you” which highlights the use of Life Extension products to prevent the progression of heart failure and links to an article titled, “Why CoQ10 is Key to Heart Health” in Life Extension Magazine, accessible at www.lifeextension.com/magazine/2014/4/coq10-proven-benefits-in-heart-fa… and includes links to product pages to several Life Extension CoQ10 products and the health protocol, “Heart Failure” listed above, where your products can be purchased directly.
Additionally, you offer for sale the e-book, Disease Prevention and Treatment, 5th Edition
, authored by Life Extension Foundation, on your website. This book includes the protocols highlighted above found on your website and includes links to www.lef.org
for updated protocols and more information. The website, www.lef.org
automatically redirects to www.lifeextension.com where your products can be purchased directly
. An example of the claims found in the book include from Chapter 25, “Brain Tumor”:
Under the subheading, “SUMMARY”:
- “Given the inadequacy of standard medical treatment in controlling high-grade malignant brain tumors, this approach of co-treating brain tumors with brain tumor-specific diet and nutritional supplementation, in addition to the medical oncology standard of care, is an option that offers hope to those afflicted with brain tumors.”
Further in the chapter, there is a link titled, “Life Extension Suggestions” which links to www.lifeextension.com
. The book lists various products, as well as two different links – one for further references and another to read the “…[M]ost current version of this protocol” on www.lifeextension.com, where your products can be purchased directly
Your Apigenin, Astragalus, Blueberry, Chrysin, and Cruciferous vegetable extract products, as well as many others, are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under Section 201(p) of the Act [21 USC 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in Sections 301(d) and 505(a) of the Act [21 USC 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.
A drug is misbranded under Section 502(f)(1) of the Act [21 USC 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in Section 503(b)(1)(A) of the Act [21 USC 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.
Furthermore, your Apigenin, Astragalus, Blueberry, Chrysin, and Cruciferous vegetable extract products, as well as many others, are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Apigenin, Astragalus, Blueberry, Chrysin, and Cruciferous vegetable extract products, as well as many others, fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].
The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may result in legal action without further notice, including, without limitation, seizure and injunction.
We note that there are over 400 products on your website that contain various disease claims. You should review your website for violations not mentioned in this letter.
Within 15 working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations noted above. Your response should include any documentation that would assist in evaluating your corrections. If you cannot complete corrective action within 15 working days, please explain the reason for the delay and the date by which each such item will be corrected.
If you need additional information or have questions concerning any products distributed through your website, please contact the FDA. Your written response should be sent to Randall L. Morris, Compliance Officer, U.S. Food and Drug Administration, 555 Winderley Place, Suite 200 Maitland, FL 32751. If your have questions regarding any issues in this letter, please contact Mr. Morris at (407) 475-4741
Susan M. Turcovski
Director, Florida District